POPULARITY
166 episodes with bill morice
131 episodes with bill morice
19 episodes with bill morice
8 episodes with bill morice
3 episodes with bill morice
2 episodes with bill morice
2 episodes with bill morice
2 episodes with bill morice
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss tick-borne diseases. They cover:Different diseases patients can get from ticks. Disease prevention, including Dr. Pritt's A through Z flash cards with tips for people to protect themselves from infectious insects.Laboratory medicine's valuable role in testing and educating providers to diagnose patients quickly and accurately.Clinical areas most likely to encounter patients with tick-borne diseases.Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories).
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered: Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.Information physicians receive from the test, and when they should consider ordering it for their patients. Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration's (FDA) oversight of lab-developed tests (LDT). They covered: Details about the ruling to vacate the FDA's rule on LDT oversight. What LDT oversight might look like in the future. How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the evolution of retail health. They cover several key topics, including:The emergence of retail health locations.Three types of care that are well-suited for a retail approach to healthcare.The importance of incorporating diagnostics when designing retail health.Keep up with the latest diagnostic news and Dr. Morice's insights on LinkedIn and X.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss infectious disease activity around the nation. They cover: The high prevalence of influenza A, avian influenza, measles, and COVID-19. Reliable resources for information on the spread of infectious diseases. Prevention measures and their impact on the spread of infectious diseases. The risks associated with multiple infectious diseases circulating simultaneously at high rates.
More with Mayo Clinic's Dr. Bill Morice as he gets into the medical community's renewed hope for cancer vaccines to become a reality. Also - the very concerning and ongoing issue of cyberattacks on hospitals and healthcare. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.
Dr. Bill Morice is the President and CEO of Mayo Clinic Labs and a professor of pathology at Mayo Clinic. Returning to the program for two segments, here he discusses liquid biopsies, their efficacy and how they'll change detecting and treating cancer. And what do humans need to be concerned over with avian influenza... or, bird flu. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.
More with Mayo Clinic's Dr. Bill Morice as he gets into the medical community's renewed hope for cancer vaccines to become a reality. Also - the very concerning and ongoing issue of cyberattacks on hospitals and healthcare. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.
Dr. Bill Morice is the President and CEO of Mayo Clinic Labs and a professor of pathology at Mayo Clinic. Returning to the program for two segments, here he discusses liquid biopsies, their efficacy and how they'll change detecting and treating cancer. And what do humans need to be concerned over with avian influenza... or, bird flu. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, for a conversation about quality management. Specifically, they discuss: The benefit of investing in quality management for patients, staff, and the organization.How Mayo Clinic's Department of Laboratory Medicine and Pathology in Rochester evolved and grew its quality management program.The advantage of holding 5–10-minute huddles each day.How the lab leverages education on quality tools and Gemba Walks to empower all staff to invest in quality management.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends. Their conversation covers: What's driving a renewed interest in investing in diagnostics.Why the knowledge pathologists have is so valuable in the current landscape.How the evolving expectations of laboratory professionals will make it important to stay informed about business trends.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss Dr. Morice's recent article in Becker's Hospital Review, “Nine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025,” and go deeper into conversation about: The rapid evolution of artificial intelligence and large language models.Digital pathology.Proteomics, metabolomics, and mass spectrometry.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss emerging concerns about H5N1 avian influenza. Specific topics of discussion include:Patterns of transmission and what they indicate about the potential of person-to-person transmission. Tools, tests, and processes that emerged in recent years that are making it easier to understand and track this virus. Remaining unknowns about the virus and how it could evolve.
This episode, recorded live at the Becker's Healthcare 12th Annual CEO + CFO Roundtable, features Dr. Bill Morice, President and CEO of Mayo Clinic Laboratories. Dr. Morice discusses key healthcare trends for 2025, including cybersecurity, artificial intelligence, reimbursement challenges, and the global push for patient-centered diagnostic ecosystems.In collaboration with R1.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the progress of artificial intelligence (AI) and what's next in this space.Specific topics of discussion include:What's driving the rapid acceleration of AI advancements.Ethical concerns and opportunities.How expenses, payment models, and culture influence AI advancements.The need to rethink training and education amid the rise of AI solutions.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest in infectious disease outbreaks. Specific topics of discussion include:Recent trends in the spread of H5 bird flu and dengue fever. Why it's important to think globally when monitoring infectious diseases.Extra precautions to take during the holiday travel season to keep you and those around you healthy.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss how labs can enhance patient access to improve health equity.Specific topics of discussion include:Innovations creating new possibilities, such as mobile clinics, at-home tests, and artificial intelligence.The responsibility of laboratory professionals to help guide the use of these new tools and the importance of collaboration between health systems.What's needed to make solutions scalable and sustainable.Learn more in Dr. Morice's “Lab Manager” article.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent outbreaks in vaccine-preventable diseases. Specific topics of discussion include:Recent increases in outbreaks of infectious diseases, such as pertussis, measles, and polio. The serious side effects of the diseases. What's fueling the resurgence of these diseases.Testing options for infectious diseases and resources for physicians.
While confirmed cases for many respiratory illnesses are currently low, they will almost certainly spread as we move further into fall and winter. Now is the perfect time to prepare and take steps to protect yourself from everything from COVID-19 and influenza to RSV and the common cold. In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss practical steps for protecting yourself and innovations that are making testing and vaccination easier. Specific topics of discussion include:The importance of vaccinations and preventive measures to keep you healthy. Innovations that are making it possible to provide more at-home options for vaccination and testing and when these options will be most beneficial. The latest status on avian influenza.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the latest news in pathogen activity and how these viruses serve as an important reminder of the role of the public-private lab partnership.Their discussion includes:How the United States addresses emerging pathogens and the importance of a partnership between public health laboratories and private or clinical laboratories.Why access to testing is vital to prevent pathogen outbreaks and pandemics.The need for an effective legal framework around pandemic and hazard preparedness.Current diagnostic efforts around mpox, bird flu, and COVID-19, and opportunities to expand at-home testing.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories' suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).Their discussion includes:Symptoms of lupus and characteristics of the complex disease process.The role of laboratory testing in diagnosing and managing long-term treatment for patients with lupus.Dr. Thomas' clinical experience using the Progentec aiSLE® DX Lupus Flare Risk Index and Lupus Disease Activity Index for his patients, and how these tests have enhanced collaborative treatment planning.Why these novel tests are a major step forward in expanding diagnostic tools and improving care for patients living with SLE.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories' suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).Their discussion includes:The Progentec aiSLE® DX Lupus Flare Risk Index that uses an algorithm to calculate a flare risk index, which assigns a score based on a patient's risk of a forthcoming lupus flare.The Progentec aiSLE® DX Lupus Disease Activity Index that characterizes a patient's current disease activity into low, moderate, or active states.How these two tests were developed and for whom they are recommended.Why these tests are a significant development and how they enhance the quality of life for patients living with SLE.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer's disease testing and treatment.Their discussion includes:Why there is an increased focus on Alzheimer's disease in the diagnostics industry.The development of groundbreaking blood tests that can detect Alzheimer's-related biomarkers.The importance of accurate testing to avoid false positives.The role of laboratory scientists in guiding appropriate test usage.The promising new treatment options and the need for informed decision-making in a patient's healthcare journey.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They cover current trends, pain points, and opportunities for growth in the lab and diagnostics market.Their discussion includes:Insights from Dr. Morice's participation in an Advisory Board webinar about 2024 lab market trends.Why there is an increased demand for laboratory testing.The opportunities that come with digital pathology, at-home testing, and remote diagnostics.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss what's new and ongoing with pathogens and infections.Their discussion includes:Summer cases of COVID-19.H5N1 (avian influenza) activity and testing options.Increasing dengue fever infections.Outbreaks of listeria and cyclospora.The importance of public-private partnerships in preventing disease outbreaks and increasing access to testing.
Dr. Bill Morice is the CEO of Mayo Clinic Laboratories and formerly was the longtime Chair of Lab Medicine and Pathology. Dr. Morice has been a regular visitor to the program since 2020. Covid cases are surging again (not like 2020 but the numbers are up coast to coast) and what of dengue fever. Currently cases in the U.S. are three times higher than they were last year at this time. Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss insights from Dr. Morice's recent travels abroad, including biomanufacturing, diagnostics, cybersecurity, and supply chain activities.Their discussion includes:What's happening in the global diagnostics industry and takeaways from visiting Saudi Arabia and Italy.Why countries are looking toward building their own biomanufacturing and diagnostic resources, and the impacts of a global supply chain.The evolution of digitalization and cybersecurity.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how healthcare is a logical space to apply artificial intelligence (AI) technology and trends in how AI is being utilized.Their discussion includes:The benefits and pitfalls of using AI in clinical settings.Important factors to consider before implementing AI tools in the laboratory.A successful AI use case from the Parasitology Lab at Mayo Clinic, and how it enhanced turnaround times and staff satisfaction.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss a case that was recently overturned by the Supreme Court of the United States that may have ramifications for the healthcare industry, including impacts on regulatory oversight.Their discussion includes:A summary of the Supreme Court ruling on June 28 to overturn the 1984 Chevron v. Natural Resources Defense Council decision, and how that impacts the power of federal agencies and the interpretations of the laws they administer. How this decision may impact current healthcare issues like reimbursement and the U.S. Food and Drug Administration's (FDA) final rule on regulating laboratory-developed tests as medical devices.The ambiguity of what comes next, and the importance of engaging members of Congress on these important decisions.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the summertime activity of COVID-19 and the latest updates with avian influenza (H5N1).Their discussion includes:The recent rise in COVID cases and how the new FLiRT variants of the virus are affecting the immune system.Updates on avian influenza activity and the risk for more mutations and human infections.How the U.S. Centers for Disease Control and Prevention (CDC) is responding to the avian flu outbreaks and how laboratories are preparing to support testing needs.Reminders of how to best protect yourself and your loved ones from infectious diseases this summer.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the platform business model and how it's being used in the healthcare industry to drive innovation and reimagine how care is provided.Their discussion includes:Key takeaways from the recent conference hosted by Mayo Clinic Platform.What constitutes a platform and how the model is being implemented in the healthcare industry.How the platform model can transform the way healthcare is delivered, and the implications this transformation has on laboratory medicine and pathology.
Tune in to the latest episode of the Becker's Healthcare Podcast, recorded live at our 14th Annual Meeting, where we delve into insightful discussions with industry experts. Join Dr. Bill Morice, CEO at Mayo Clinic Laboratories, as they share invaluable insights on leadership, growth strategies, and navigating workforce challenges in healthcare. Gain actionable advice and best practices to elevate your organization's performance in today's dynamic landscape.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss why measles remains a virus of concern, how avian flu continues to spread, and new developments in the federal regulation of laboratory-developed tests.Their discussion includes:How a person infected with measles recently traveled through a U.S. airport, and the severity of the measles virus.The continued deadly spread of avian flu among wild birds, domestic poultry, and cattle, and the infection of a third human.Avian flu vaccine development and the importance of emergency preparedness.The American Clinical Laboratory Association's (ACLA) lawsuit against the U.S. Food and Drug Administration (FDA) regarding the agency's final rule to treat laboratory-developed tests as medical devices.
Dr. Bill Morice is the President and CEO of Mayo Clinic Labs and a longtime regular on The CGP. He returns to talk about what the concern level for measles should be when someone has it and shows up in your city. Also, what you need to know when traveling abroad relative to medical concerns that almost always are overlooked. See omnystudio.com/listener for privacy information.
In this special episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the final rule issued by the U.S. Food and Drug Administration (FDA) on April 29, 2024, to make explicit its plan to regulate laboratory-developed tests (LDT) as medical devices under the Federal Food, Drug, and Cosmetic Act.Their discussion includes:Highlighting key points, exceptions, and the phased implementation plan of the final rule.How the FDA's final rule compares to its proposed rule from last year.How the news may impact laboratories, health systems, health agencies, and manufacturers.Uncertainties that still remain regarding the future of laboratory-developed tests.
Dr. Bill Morice is the CEO of Mayo Clinic Labs, the former Chair of Lab Medicine and Pathology at Mayo Clinic and a CGP regular. He returned to the program to discuss Measles and how cases globally are rising, Alzheimer's / Dementia / Early Onset Dementia and when pulmonary nodules are, and aren't, serious. See omnystudio.com/listener for privacy information.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer's disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare.Their discussion includes:The latest news about the U.S. Food and Drug Administration's (FDA) proposed rule around regulating lab-developed tests.New testing innovations for Alzheimer's disease and cognitive impairments, including Mayo Clinic Laboratories' plasma biomarker testing for Alzheimer's disease. The importance of being responsible lab stewards and working closely with clinicians to understand how different testing approaches drive decision-making in healthcare settings.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including Medical Laboratory Professionals Week, recent healthcare conferences, advocacy efforts, measles, and bird flu.Their discussion includes:Key takeaways from the Becker's Healthcare Annual Meeting and the College of American Pathologists' (CAP) Pathologists Leadership Summit.The resurgence of measles cases and recent activity of bird flu (H5N1).Tips for staying engaged and being the voice for patients.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.Their discussion includes:The surge of dengue cases in Latin America, and best practices for tick and mosquito bite prevention.Advancements in laboratory tests and technology used for colon cancer screening.Issues with insurers paying for new screening technology versus routine screening methods.How laboratorians can help educate physicians and policymakers on how innovative laboratory tests create value for patients and the entire healthcare system.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss important industry updates and legislative insights gathered from Dr. Morice's recent trip to Washington, D.C.Their discussion includes:The status of current laboratory-related legislative efforts, including the Protecting Access to Medicare Act (PAMA), the Saving Access to Laboratory Services Act (SALSA), and the Pandemic and All Hazards Preparedness Act (PAHPA).Current issues facing the laboratory industry, including prior authorization, coding, and potential FDA oversight of laboratory-developed tests.The importance of advocating on behalf of laboratories, clinicians, and patients, and engagement opportunities through professional societies like the College of American Pathologists and the American Clinical Laboratory Association.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the Food and Drug Administration's (FDA) progress on making a final rule around regulating laboratory-developed tests (LDTs). Their discussion includes:How the FDA's proposed rule on regulating LDTs has advanced to the White House Office of Management and Budget (OMB) for review, and what to expect in the coming months.Ongoing work around the Saving Access to Laboratory Services Act (SALSA).How laboratorians and pathologists can stay engaged on these important issues.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to honor Black History Month. They reflect on important advancements in healthcare and laboratory medicine that were led by Black healthcare professionals and scholars. They also discuss health inequities that impact communities throughout the United States. Their discussion includes:A few of the major advancements in the medical field made by Black scholars, nurses, doctors, and surgeons, and important contributions to laboratory medicine by pioneering Black physicians and physician-scientists.Health inequities, accessibility issues, and diseases that are more prevalent in African Americans and people of lower socioeconomic status.How misinformation impacts preventive health measures.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss current activity of infectious diseases.Their discussion includes:Vector-borne diseases that are causing public health concerns, and the multi-agency public health strategy recently released by the U.S. Department of Health and Human Services to address the growing problem.The benefits of a public-private, collaborative approach to public health, and why laboratorians need to be involved.Both new and reemerging diseases that are being found across the United States, and how laboratory-developed tests play a vital role in diagnosing and managing these diseases.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss what companies in the healthcare and diagnostics industries are focusing on in 2024.Their discussion includes:Insights from the J.P. Morgan Healthcare Conference, and where investments are happening in the diagnostics industry.Observations from visiting Southeast Asia around international healthcare innovation and testing accessibility. The importance of private-public partnerships and investments to advance global health.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to welcome the new year and discuss the increase of respiratory viruses.Their discussion includes:The increasing number of COVID-19 and influenza cases across the United States.The endemic state of COVID-19 and tools for prevention.The continued need to protect public health and advocate for the reauthorization of the Pandemic and All-Hazards Preparedness Act.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to reflect on key moments from 2023 and to discuss what may lie ahead in 2024.Their discussion includes: A look back at impactful events from 2023 in laboratory medicine and diagnostics. What's top of mind today heading into the holidays. Speculating about industry trends to expect in 2024.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration's (FDA) recent approval of two gene therapies for sickle cell disease.Their discussion includes: The cause and characteristics of sickle cell disease. How the new cell-based gene therapies, Casgevy and Lyfgenia, work in the body. Bioethical and accessibility considerations of innovative treatments like gene-editing therapies. A brief update on the status of the FDA's proposed rule on laboratory-developed tests.
© 2020-2025 Ivy Podcast Discovery LLC
